Data regarding treatment for<unk>  is limited and draws on a combination of observational case series and case reports. There have been no randomized controlled trials investigating treatment options for<unk> . Surgical removal of enlarged lymph nodes, the standard treatment for UCD, is ineffective in<unk> . Like iMCD,<unk>  is treated with medications. Factors influencing medication selection include disease severity, presence of HIV, presence of Kaposi sarcoma, and response to prior treatments. Rituximab, a drug that depletes B cells, is the first line agent for patients with<unk>  and is recommended in all patients with proven<unk>  unless they have a contraindication to the medication or have failed treatment with the medication in the past. For patients who present with severe organ dysfunction, develop worsening organ dysfunction despite treatment with Rituximab, or have concurrent Kaposi sarcoma, additional chemotherapeutic agents are added to Rituximab. All patients with HIV should continue or initiate treatment with antiretroviral therapy. Antiviral medications targeted at<unk> -8, such as valganciclovir, may be used in patients with poorly controlled HIV or concurrent Kaposi sarcoma. Rituximab may be discontinued once clinical and laboratory evidence of active disease resolve or continued as maintenance therapy. Patients who responded to Rituximab but have recurrent<unk>  after discontinuing the medication typically respond to retreatment with Rituximab. Follow-up Patients with<unk>  are typically seen at routine intervals for assessment of treatment response and disease progression. Follow-up visits may include evaluation of symptoms, physical examination, laboratory testing, and radiologic imaging.
HHV-8-associated MCD
Cytomegalic inclusion body disease
Epstein–Barr virus–associated lymphoproliferative diseases
AIDS-related lymphoma
Fibrin-associated diffuse large B-cell lymphoma
Tuberculosis in relation to HIV
Hepatitis C and HIV coinfection
Epstein–Barr virus infection